IGF::OT::IGF THE EFFECT OF INTERMITTENT VERSUS CONTINUOUS DOSE ASPIRIN (ASA) IN CURRENT SMOKERS ON NASAL EPITHELIUM GENE EXPRESSION

IGF::OT::IGF 当前吸烟者间歇服用与连续服用阿司匹林 (ASA) 对鼻上皮基因表达的影响

• 批准号: 9162585
• 负责人: SHERRY CHOW
• 金额: $ 15.68万
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-01 至 2017-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9162585
• 关键词: Arizona; Aspirin; Boston; Data Analyses; Dose; Gender; Gene Expression; Gene Expression Profile; Genes; Genome; Intervention; Malignant Neoplasms; Malignant neoplasm of lung; Manuscripts; Nasal Epithelium; Participant; Patient Care; Preparation; Reporting; Safety; Schedule; Smoker; Smoking; Universities; cohort; lung cancer prevention; urinary

The proposed study shall assess the effects of aspirin 81 mg per day dose given either continuously or intermittently (1 week on/1 week off schedule) for 3 months on selected smoking-related gene expression signature and three lung cancer-related signatures in the nasal epithelium of current smokers, and to evaluate any difference between both aspirin dosing groups. This study is an early step in larger effort to evaluate whether or not aspirin could be useful in prevention of lung cancer. The trial shall be performed at the University of Arizona, which shall be responsible for participant recruitment, patient care, data analysis, report preparation, and manuscript preparation. Boston University (Dr. A. Spira�s group), a collaborator on this study, shall be responsible for all gene signatures related analyses.

拟定研究应评估阿司匹林81 mg/天剂量连续或间歇（给药1周/停药1周）给药3个月对当前吸烟者鼻上皮中选定吸烟相关基因表达特征和3种肺癌相关特征的影响，并评价两个阿司匹林给药组之间的任何差异。这项研究是更大努力的早期步骤，以评估阿司匹林是否有助于预防肺癌。试验应在亚利桑那大学进行，该大学应负责受试者招募、患者护理、数据分析、报告编写和手稿编写。波士顿大学（A. Spira的小组），这项研究的合作者，将负责所有基因签名相关的分析。